Figure Sample Clauses

Figure. (a) If the applicant fails to make the indication referred to in Rule 3.3(a)(iii), or if the International Searching Authority finds that a figure or figures other than that figure or those figures suggested by the applicant would, among all the figures of all the drawings, better characterize the invention, it shall, subject to paragraph (b), indicate the figure or figures which should accompany the abstract when the latter is published by the International Bureau. In such case, the abstract shall be accompanied by the figure or figures so indicated by the International Searching Authority. Otherwise, the abstract shall, subject to paragraph (b), be accompanied by the figure or figures suggested by the applicant.
Figure. 3 Growth of yeast cells expressing the wild-type adenosine A2B receptor or the N43S mutant receptor. Growth was measured in the absence (control) or presence of 10 µM NECA or 10 µM ZM241385. Each experiment was repeated 3 times, of which the means SEM are shown. *** p 0.001, student’s unpaired t test. Matlab was used to mimic the activation and inhibition of receptors with a high level of constitutive activity (L 1000). The a values were set from 100 for an agonist to 0.1 and 0.01 for inverse agonists. As shown in figure 4, it is hard to detect agonism and inverse agonism of a ligand on receptors with such a big L value. In other words, this receptor is locked in an active state and can not be further activated or inhibited.
Figure. 8 A) Three-dimensional mesh of the percentage of maximum theoretical window for hypothetic inverse agonists with continuous intrinsic efficacy (α) values between 0.001 to 1 on hypothetic receptors with continuous ratios of active versus inactive receptors (L values) between 0.001 to 1000. In figure 8B, concentration-response curves are shown for receptors with L values of 0.01, 1, 10 and 100 for a strong inverse agonist with an a value of 0.001 (closed circles in figure 8A). Similarly, in figure 8C, concentration-response curves are shown for a weak inverse agonist with an a value of 0.1 (open circles in figure 8A). (z-axis) and the percentage of the maximum theoretical window (y-axis) can be visualized in a 3-D mesh (see Figure 8A). A series of bell-shaped curves represent the percentage of the maximum theoretical window that can be achieved when log α and log L are varied. This mesh shows that for a ligand with an α value between 0.001 and 1 an optimal theoretical window can be achieved for receptors with a log L value close to 1. Within the framework of the two-state receptor model, the theoretical window ( ρ0-ρ∞ ) is calculated as L/(L+1)- aL/(1+aL) . An optimal theoretical window will be obtained when the relationship between the level of constitutive activity (L) of a receptor and the α value of the ligand obeys the following equation α L = 1 equation 5 The 3-D mesh is composed of a series of bell-shaped curve according to the different intrinsic efficacies of a ligand. The maximum is achieved when L equals the reciprocal square root of
Figure. 1-1. A schematic view of the FMR1 gene. The FMR1 gene spans 38 kb on the X chromosome and contains 17 Exons. The CGG repeats are located in the first exon of FMR1 gene which encodes the 5′ UTR of Fmr1 mRNA. FMR1 CGG repeats are classified to three groups, typical (or normal), permutations and full mutation according to the number of repeats. The disease pathology in premutation is different from full mutation. Excess mRNA transcripts in premutation carriers lead to less FMRP protein and cause fragile X-associated tremor/ataxia syndrome. Only the absence of FMRP in individuals with full mutations results in Fragile X syndrome. Figure 1-2 Figure. 1-2. A schematic of FMRP protein. FMRP protein contains three well- characterized RNA binding domains: XX0, XX0 and RGG box. FMRP protein possesses one nuclear localization signal (NLS) and one nuclear export signal (NES), which together enable FMRP shuttling between the nucleus and the cytoplasm. Chapter II Fragile X Mental Retardation Protein Regulates Protein Expression and mRNA Translation of the Potassium Channel Kv4.2 Published in Gross et al., Journal of Neuroscience 2011; 31(15):5693-5698 Xxxxxxxxx Gross1,*, Xiaodi Yao1,*, Xxx X. Pong1, Andreas Jeromin3, and Xxxx X. Bassell1,2 1Departments of Cell Biology and 2Neurology, Emory University School of Medicine, Xxxxxxx, Xxxxxxx 00000, and 3Banyan Biomarkers, Inc., Xxxxxxx, Xxxxxxx 00000 Author contributions: C.G., X.Y., and G.J.B. designed research; C.G., X.Y., and D.L.P. performed research; C.G., X.Y., D.L.P., A.J., and G.J.B. analyzed data; C.G., X.Y., and
Figure. 4 Distribution of the 419 lakes used for the creation of the models among European map. GIGs (Alpine (AL), Central- Baltic (CB), Mediterranean (MED) and Nordic (NO)) are represented in colour.
Figure. 3.4-10 At a dose of 0.1, 0.3, and 1 mg/kg, URB597 does not affect locomotion 88
Figure. 3.4 depicts some real visual FROG head nod detection results, while Figure 3.5 depicts some real visual FROG head shake detection results.
Figure. 5 The only category which may do multiple IGOs or task orders for a single project is Conservation Initiatives. Each agency involved in an Inter-agency Conservation Initiative will require a separate IGO or task order to conduct its portion of Conservation Initiative project. Project teams should determine the portion of total project funds available that will be required by each agency for its part of the project, so that each agency receives only one IGO/task order for each project in which it’s involved. The agencies are to ensure that their reimbursable account number is provided to the BLM contracting officer or identified on the IGO by the agency authorized representative before signing the IGO and returning to the BLM Contracting Officer for signature. Agencies/entities should make every effort to execute IGOs and task orders within 60 days of submission to them for signature. Projects may be considered for termination if IGOs and task orders are not executed in a timely manner. Projects terminated for this reason may be re- submitted in a subsequent round when the agency is ready to move forward.
Figure. 8.3 Guiding Principles in Drafting Rule 9 Expressions, Etc., Not To Be Used
Figure. An e-prescription and its transmission involves a complex set of data elements that are currently tailored to the specific needs of the member state application. The ePrescription use case Within the prescription area there are two basic generic use cases.